Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Older people, immunocompromised people and those with underlying health conditions can benefit most from additional shots.
This marks the first-in-class bispecific antibody, a type of immunotherapy, approved to treat any type of non-Hodgkin lymphoma.
Rezlidhia (olutasidenib) is approved as a targeted treatment option for adults whose acute myeloid leukemia carries the IDH1 mutation.
Researchers at the American Cancer Society stress health interventions to continue reducing nicotine pouch use.
Patient advocate Melvin Mann was diagnosed with chronic myeloid leukemia in 1995. He has been in treatment and in remission since 1998.
Updated Pfizer-BioNTech and Moderna bivalent boosters contain spike proteins from the original and BA.4 and BA.5 omicron variants.
Currently, only 5% of oncology drugs have been approved for first time use in children.
Updated boosters could go to the “worried well” who have good insurance rather than to those at highest risk.
Squamous cell carcinoma and lymphomas have been reported in the scar tissue of breast implants, but the FDA believes the risk is rare.
The engineered protein vaccine was highly effective in a clinical trial but faced a long delay for authorization.
Tobacco control researchers say this proposed change could have the greatest impact on youth and African American smokers.
An unusual alliance among senators emerged in the push to allow for the importation of drugs from Canada and the United Kingdom.
Azacitidine (Vidaza) was approved for pediatric patients with newly diagnosed juvenile myelomonocytic leukemia (JMML).
After a long wait, the FDA authorizes Pfizer and Moderna vaccines for children as young as 6 months old.
People who received the combination lived longer without experiencing serious events, including their cancer returning.
A study found that only 43% of clinical trials reported race and ethnicity. The FDA issued guidance to address these inequalities.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.